Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1996-06-19
1997-08-05
Grumbling, Matthew V.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
540527, 540524, 540488, 540490, 540523, 540492, 540500, 544 54, 544 47, 544 90, 546138, 514211, 5142272, 514306, 5142268, 5142305, 514221, 514218, A61K 3155, C07D40312, C07D40314, C07D22312
Patent
active
056542941
ABSTRACT:
Compounds of the formula ##STR1## are disclosed as possessing inhibotory activity against angiotensin converting enzyme (ACE) and neutral endopeptidase (NEP) and thus being useful as cardiovascular agents. Processes for preparing these compounds are also disclosed.
REFERENCES:
patent: 4105776 (1978-08-01), Ondetti et al.
patent: 4192945 (1980-03-01), Ondetti
patent: 4339600 (1982-07-01), Ondetti et al.
patent: 4374829 (1983-02-01), Harris et al.
patent: 4409146 (1983-10-01), Thorsett
patent: 4410520 (1983-10-01), Watthey
patent: 4415496 (1983-11-01), Harris et al.
patent: 4460579 (1984-07-01), Karanewsky
patent: 4465679 (1984-08-01), Huang et al.
patent: 4470988 (1984-09-01), Watthey
patent: 4473575 (1984-09-01), Watthey
patent: 4474778 (1984-10-01), Gordon et al.
patent: 4477464 (1984-10-01), Slade et al.
patent: 4512924 (1985-04-01), Attwood et al.
patent: 4537885 (1985-08-01), Watthey
patent: 4539150 (1985-09-01), Katakami et al.
patent: 4548932 (1985-10-01), Sugihara et al.
patent: 4575503 (1986-03-01), Watthey
patent: 4584294 (1986-04-01), Ruyle
patent: 4587050 (1986-05-01), Harris et al.
patent: 4587238 (1986-05-01), Harris et al.
patent: 4594341 (1986-06-01), Cheung et al.
patent: 4617301 (1986-10-01), Patchett et al.
patent: 4629787 (1986-12-01), Harris et al.
patent: 4666901 (1987-05-01), Parsons
patent: 4680392 (1987-07-01), Harris et al.
patent: 4699905 (1987-10-01), Yangisawa et al.
patent: 4711884 (1987-12-01), Karanewsky
patent: 4734410 (1988-03-01), Yarazisawa et al.
patent: 4749688 (1988-06-01), Haslanger
patent: 4824832 (1989-04-01), Flynn et al.
patent: 4873235 (1989-10-01), Parsons et al.
patent: 4963539 (1990-10-01), Delaney
patent: 4973585 (1990-11-01), Flynn et al.
patent: 5075302 (1991-12-01), Neustadt
patent: 5098934 (1992-03-01), Vevert et al.
patent: 5190974 (1993-03-01), Clemence et al.
patent: 5208236 (1993-05-01), Neustadt
patent: 5223516 (1993-06-01), Dalaney
patent: 5225401 (1993-07-01), Seymour
patent: 5232920 (1993-08-01), Neustadt
patent: 5238924 (1993-08-01), Smith
patent: 5262436 (1993-11-01), Haslanger et al.
patent: 5362727 (1994-11-01), Robl
patent: 5366973 (1994-11-01), Flynn et al.
Boyer, T.D. "Cirrhosis of the Liver and Its Major Sequelae" in: Wyngaardon, J.B., et al., Gril Textbook of Medicine vol. 1 (Philadelphia, Saunders Co., 1992), pp. 786-789.
Robl, J.A. et al. Bioorg. Med. Chem. Lett. 4, 1795-1800 (1994).
Robl et al., Biiorganic & Medicinal Chem. Letters, vol. 4, pp. 1795-1800, 1994 Month of Publication Not Provided.
Dussaule et al., Jour. of Clinical Endocrinology and Metabolism, vol. 72, pp. 653-659, 1991 Month of Publication Not Provided.
Loffi et al., Gastroenterology, vol. 96, pp. 167-177, 1989 Month of Publication Not Provided.
Fyhrquist et al., The Lancet, Dec. 21/28, 1985, p. 1439 Month of Publication Not Provided.
Fernandez-Cruz, The Lancet, Dec. 21/28, 1985, pp. 1439-1440 Month of Publication Not Provided.
Naming and Indexing of Chemical Substances for Chemical Abstracts, 1987 Index Guide, Section 203 Month of Publication Not Provided.
Watthey et al., J. Med. Chem., 28, pp. 1511-1516 (1985) Publication Month Not Provided.
Slade et al., J. Med. Chem., 28, pp. 1517-1521 (1985) Publication Month Not Provided.
Thorsett et al., J. Med. Chem., 29, pp. 251-260 (1986) Publication Month Not Provided.
Yanagisawa et al., J. Med. Chem., 30, pp. 1984-1991 (1987) Publication Month Not Provided.
Yanagisawa et al., J. Med. Chem., 31, pp. 422-428 (1988) Publication Month Not Provided.
Parsons et al., Biochem and Biophysical Research Comm. 117, pp. 108-113 (1993) Publication Month Not Provided.
Atwood et al., FEBS Letters, vol. 165, pp. 201-206 (1984) Publication Month Not Provided.
Natoff et al., Drugs Of the Future, vol. 12, pp. 475-483 (1987) Publication Month Not Provided.
Itoh et al., Chem. Pharm. Bull., vol. 34, pp. 1128-1147 and 2078-2089 (1986) Publication Month Not Provided.
Flynn, Tetrahedron Letters, vol. 31, pp. 815-818 (1990) Publication Month Not Provided.
Thorsett, Actual Chim. Ther., vol. 13, pp. 257-268 (1986) Publication Month Not Provided.
Atwood et al., J. Chem. Soc. Perkin Trans I (1986) pp. 1011-1019 Publication Month Not Provided.
Robl, Tetrahedron Letters, vol. 35, pp. 393-396 and 1393-1396, (1994) Publication Month Not Provided.
Delaney et al., Bioorganic & Medicinal Chemistry Letters, vol. 4, pp. 1783-1788 (1994) Publication Month Not Provided.
Robl et al., Bioorganic & Medicinal Chemistry Letters, vol. 4, pp. 1789-1794 (1994) Publication Month Not Provided.
Robl et al., Bioorganic & Medicinal Chemistry Letters, vol. 4, pp. 2055-2060 (1994) Publication Month Not Provided.
Das et al., Bioorganic & Medicinal Chemistry Letters, vol. 4, pp. 2193-2198 (1994) Publication Month Not Provided.
Bolos et al., J. Org. Chem., 57, 3535-3539 (1992) Publication Month Not Provided.
Bolos et al., Tetrahedron, vol. 48, pp. 9567-9576 (1992) Publication Month Not Provided.
Adams et al., Synthetic Communciations, vol. 18, 2225-2231 (1988) Publication Month Not Provided.
Chackalamannil et al., Bioorganic & Medicinal Chemistry Letters, vol. 2, pp. 1003-1006 (1992) Publication Month Not Provided.
Flynn et al., J. Med. Chem., 36, pp. 2420-2423 (1993) Publication Month Not Provided.
Robl et al., J. Am. Chem. Soc., 116, pp. 2348-2355 (1994) Publication Month Not Provided.
Bristol-Myers Squibb
Davis Stephen B.
Grumbling Matthew V.
Wong King Lit
LandOfFree
Spiro lactam dual action inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Spiro lactam dual action inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Spiro lactam dual action inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1074941